Diagnostic value of 11C-methionine (MET) and 18F-fluorothymidine (FLT) positron emission tomography in recurrent high-grade gliomas; differentiation from treatment-induced tissue necrosis

Cancers

Volumn 4, Issue 1, 2012, Pages 244-256

  Shishido, Hajime ^a   Kawai, Nobuyuki ^a   Miyake, Keisuke ^a   Yamamoto, Yuka ^b   Nishiyama, Yoshihiro ^b   Tamiya, Takashi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Fluorothymidine (FLT); Malignant glioma; Methionine (MET); Necrosis; Positron emission tomography; Recurrence

Indexed keywords

3' FLUOROTHYMIDINE F 18; METHIONINE C 11; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; LESION TO NORMAL TISSUE COUNT DENSITY RATIO; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MEDICAL PARAMETERS; PHARMACOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TISSUE NECROSIS;

EID: 84859037747     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4010244     Document Type: Article

References (39)

1. Wallner, K.F.; Galicich, J.H.; Krol, G.; Arbit, E.; Malkin, M.G. Patterns of failure following treatment for glioblastoma and anaplastic astrocytomas. Int. J. Radial Oncol. Biol. Phys. 1989, 16, 140-149.
2. Burger, P.C. Malignant astrocytic neoplasm: Classification, pathologic anatomy, and response to treatment. Semin. Oncol. 1986, 13, 16-26.
3. Dooms, G.C.; Hecht, S.; Brant-Zawadzki, M.; Berthiaume, Y; Norman, D.; Newton, T.H. Brain radiation lesions: MR imaging. Radiology 1986, 158, 149-155.
4. nC-methionine PET for differential diagnosis of low-grade gliomas. Neurology 1998, 50, 1316-1322.
5. nC]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNRAm. J. Neuroradiol. 2006, 27, 1432-1437.
6. Kaschten, B.; Stevenaert, A.; Sadzot, B.; Deprez, M.; Degueldre, C; Fiore, G.D.; Luxen, A.; Reznik, M. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J. Nucl. Med. 1998, 39, 778-785.
7. 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur. J. Nucl. Med. Mol. I. 2008, 35, 2009-2017.
8. nC-methionine and survival in patients with low-grade gliomas. Cancer 2001, 92, 2541-1549.
9. nC-methionine PET in suspected recurrence of glioma: Sensitivity, inter-observer variability and prognostic value. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 39-51.
10. nC] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J. Neurosurg. 2005, 103, 498-507.
11. nC-methionine PET as a marker for the radiosensitivity of low grade gliomas. Eur. J. Nucl. Med. 2002, 29, 632-640.
12. nC]methionine PET in patients with low-grade astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 43-52.
13. nC-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 516-524.
14. Tsuyuguchi, N.; Takami, T.; Sunada, I.; Iwai, Y; Yamanaka, K.; Tanaka, K.; Nishikawa, M.; Ohata, K.; Torii, K.; Morino, M., et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery-In malignant glioma. Ann. Nucl. Med. 2004, 18, 291-296.
15. nC-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J. Nucl. Med. 2008, 49, 694-699.
16. nC]methionine uptake in brain abscess: A PET study. J. Comput. Assist. Tomogr. 1993, 17, 660-661.
17. 18F-fDG PET and 99mTc-HMPOA SPECT. Ann. Nucl. Med. 2002, 16, 207-211.
18. 18F-FDG. J. Nucl. Med. 2005, 46, 945-952.
19. 18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 653-659.
20. Saga, T; Kawashima, H; Araki, N.; Takahashi, J.A.; Nakashima, Y; Higashi, T; Oya, N.; Murai, T; Hojo, M.; Hashimoto, N. et al. Evaluation of primary brain tumors with FLT-PET: Usefulness and limitations. Clin. Nucl. Med. 2006, 31, 774-780.
21. Shiels, A.F; Grierson, J.R; Dohmen, B.M.; Machulla, H.J.; Stayanoff, J.C.; Lawhorn-Crews, J.M.; Obradovich, J.E.; Muzik, O.; Mangner, TJ. Imaging proliferation in vivo with [F-18JFLT and positron emission tomography. Nat. Med. 1998, 4, 1334-1336
22. 18F]FLT-PET in oncology: Current status and opportunities. Eur. J. Nucl. Med. Mol. Imaging 2004, 31, 1659-1672.
23. nC-methylmethionine as markers of increased transport and proliferation in brain tumors. J. Nucl. Med. 2005, 46, 1948-1958.
24. Yamamoto, Y; Wong, T.Z.; Turkington, T.G.; Hawk, T.C.; Reardon, D.A.; Coleman, R.E. 3'-deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: Comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol. Imaging Biol. 2006, 8, 340-347.
25. 18F]fluorothymidine positron emission tomography in recurrent brain tumor. J. Comput. Assist. Tomogr. 2011, 35, 679-684.
26. Ostergaard, L.; Hochberg, EH.; Rabinov, J.D.; Sorensen, A.G.; Lev, M.; Kim, L.; Weisskoff, R.M.; Gonzales, R.G.; Gyldensted, G.; Rosen, B.R. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J. Neurosurg. 1999, 90, 300-305.
27. nC-methionine in the determination of malignancy of gliomas. J. Neurol. Sci. 2006, 246, 85-94.
28. Ogawa, T.; Hatazawa, J.; Inugami, A.; Murakami, M.; Fujita, H.; Shimosegawa, E.; Noguchi, K.; Okudera, T; Kanno, I.; Uemura, K., et al. Carbon-11-methionine PET evaluation of intracerebral hematoma: Distinguishing neoplastic from non-neoplastic hematoma. J. Nucl. Med. 1995, 36, 2175-2179.
29. 18F-FDG PET. Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 52-59.
30. Okubo, S.; Zhen, H.N.; Kawai, N.; Nishiyama, Y; Haba, R.; Tamiya, T. Correlation of L-methyl-HC-methionine (MET) uptake with L-type amino acid transporter 1 in human gliomas. J. Neurooncol. 2010, 99, 217-225.
31. nC]-L-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur. J. Nucl. Med. Mol. Imaging 2003, 30, 868-873.
32. Tsuyuguchi, N.; Takami, T; Sunada, I.; Iwai, Y; Yamanaka, K.; Tanaka, K.; NIshikawa, M.; Ohata, K.; Torii, T.; Morino, M., et al. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery: In malignant glioma. Ann. Nucl. Med. 2004, 18, 291-296.
33. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl. Med. Biol. 2002, 29, 281-287.
34. nC]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions. Acta Neurol. Belg. 1999, 99, 118-125.
35. 18F-fluorothymidine in patients with gliomas. J. Nucl. Med. 2006, 47, 1612-1621.
36. 18F-fluorothymidine kinetics of malignant brain tumors. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 4714-4721.
37. Dandois, V; Rommel, D.; Renard, L.; Jamart, J.; Cosnard, G. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of treated high-grade gliomas: Preliminary results in clinical practice. J. Neuroradiol. 2010, 34, 89-97.
38. 18F]FLT). J. Radioanal. Nucl. Chem. 2000, 24, 843-846.
39. nC]methionine. Appl. Radiat. hot. 1998, 39, 311-314.